The startup develops vaccine adjuvants and immunotherapy agents that enhance the innate immune response, providing life science companies with technologies for prophylactic and therapeutic applications. Their products improve the safety, efficacy, and availability of vaccine immunotherapies, addressing the need for more effective immune system support in healthcare.
Funding
$830K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many modern vaccines and future immunotherapies require adjuvants to enhance their effectiveness, but there is a need for newer and more diverse adjuvant options, including novel cellular technologies like Virus Like Particles (VLPs). Current limitations include challenges in stimulating broad and complex immune responses, addressing patient populations with impaired immune systems, and the limited immunogenicity of recombinant antigens.
Solution
Clarus Biologics develops next-generation vaccine adjuvants and immunotherapy agents based on a novel VLP technology (CBI-3A) designed to enhance the innate immune response. CBI-3A elicits immune responses from all three elements of the adaptive immune system and is particularly adept at stimulating the innate immune response. The VLP platform aims to improve vaccine safety, efficacy, and availability by providing a versatile tool applicable to various antigens and pathogens. Pre-clinical studies have demonstrated stronger immune responses compared to antigen or vaccine alone, including antibody, T-cell, and mucosal immune responses, even with intramuscular administration. The technology also offers antigen-sparing capabilities, potentially reducing costs and mitigating supply constraints.
Target Audience
Clarus Biologics targets life science companies developing vaccines and immunotherapies, particularly those seeking to improve the effectiveness, safety, and availability of their products.
Features
- Novel Virus Like Particle (VLP) adjuvant technology (CBI-3A)
- Stimulation of innate and adaptive immune responses
- Broad patent protection
- Demonstrated safety and efficacy across multiple species in pre-clinical studies
- Capability to elicit antibody, T-cell, and mucosal immune responses
- Antigen sparing capabilities
- Potential for rapid response to future vaccine and immunotherapy needs